局部作用阴道制剂仿制药评价要点

田洁, 常艳艳, 龚青, 孙桂霞

中国药学杂志 ›› 2018, Vol. 53 ›› Issue (18) : 1608-1612.

PDF(1039 KB)
中国药学杂志
PDF(1039 KB)
中国药学杂志 ›› 2018, Vol. 53 ›› Issue (18) : 1608-1612. DOI: 10.11669/cpj.2018.18.016
论著

局部作用阴道制剂仿制药评价要点

  • 田洁, 常艳艳, 龚青, 孙桂霞
作者信息 +

Discussion on the Main Review and Evaluation Points of the Consistency of Quality and Efficacy of Topical Vaginal Preparations

  • TIAN Jie, CHANG Yan-yan, GONG Qing, SUN Gui-xia
Author information +
文章历史 +

摘要

目的 局部作用阴道制剂是一类经阴道途径给药,发挥局部作用的制剂,本文探讨了该类制剂仿制药的评价要点,为国内阴道制剂仿制药的研发与审评提供借鉴。方法 通过文献调研,收集美国、欧盟、日本及中国的阴道制剂的批准上市情况及药典收载情况,探讨美国食品药品监督管理局(FDA)及欧洲药品管理局(EMA)关于局部作用阴道制剂仿制药的审评要求,分析了该类仿制药与原研药进行质量与疗效一致性的技术要点。结果与结论 该类仿制药的药学研究需关注处方工艺的合理性、关键质量属性研究的合理性、批间一致性及与原研产品的一致性。FDA和EMA通常以临床试验研究来评价该类仿制药与原研制剂的疗效和安全的一致性,一般需要大量受试者。

Abstract

Topical vaginal preparations are administered via vaginal channels to play a local role. This paper discussed review points of vaginal generic drugs in order to provide references for research and review of this drugs in china. METHODS By literature research, the paper collected the approval information and the pharmacopoeia record information of the USA, the EU, the JP and the China, discussed the review points of vaginal generic drugs in combination with the review requests of FDA and EMA, and analyzed the technical points of the quality and efficacy of vaginal generic drugs. RESULTS AND CONCLUSION S The pharmacy researches on vaginal generic drugs should focus on the rationality of prescription, process and critical quality attribute researches, concerned the consistence of inter-batch and reference listed drug. FDA and EMA usually review the equivalence of efficacy and safety with clinical trials which often need a great deal of volunteers.

关键词

局部作用 / 阴道制剂 / 生物等效性 / 审评要求

Key words

Local effect / Vaginal preparation / Bioequivalence / review points

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
田洁, 常艳艳, 龚青, 孙桂霞. 局部作用阴道制剂仿制药评价要点[J]. 中国药学杂志, 2018, 53(18): 1608-1612 https://doi.org/10.11669/cpj.2018.18.016
TIAN Jie, CHANG Yan-yan, GONG Qing, SUN Gui-xia. Discussion on the Main Review and Evaluation Points of the Consistency of Quality and Efficacy of Topical Vaginal Preparations[J]. Chinese Pharmaceutical Journal, 2018, 53(18): 1608-1612 https://doi.org/10.11669/cpj.2018.18.016
中图分类号： R926    R979.6   

参考文献

[1] BP(2017)General Notices(British Pharmacopoeia 2017年版.<1164>). 2017:1-4.
[2] Ch.P(2015)四部(中国药典2015年版.四部). 2015:3-4.
[3] Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents. 1995. http://www.emau.europa.eu.
[4] Yazhi Database. 2017-9-1 . http://www. db. yaozh. com.
[5] Yaodu Database. 2017-7-4 . http://www. data. pharmacodia. com.
[6] CFDA Domestric Drug Database. 2017-12-7. http://www.sfda.gov.cn/datasearchp.
[7] USP(40) Monographs (USP40-NF35. Monographs). 2017.
[8] BP(2017)Monographs(British Pharmacopoeia 2017年版. Volume I& II). 2017.
[9] Ch.P(2015)第二部(中国药典2015年版.二部). 2015:81-1420.
[10] JP(16)XV(Japanese Pharmacopoeia 16版. XV). 2016:7-19.
[11] Larissa Laptena, M.D.,M.H.S. GDUFA regulatory science program public meeting. 2015-6-5. http://www.fda.gov/.
[12] Guidance on Topical Dermatologic Corticosteroids: in vivo bioequivalence.1995-6-2. http://www.fda.gov/.
[13] MARKHAM C. LUKE, MD PHD. Equivalence of locally-acting drug products. 2017-5-3. http://www.fda.gov/.
[14] Draft guidance on butoconazole nitrate . 2011-3. http://www.fda.gov/.
[15] Draft guidance on clindamycin phosphate. 2012-3. http://www.fda.gov/.
[16] Draft guidance on clotrimazole. 2009-11.http://www.fda.gov/.
[17] Draft guidance on dinoprostone. 2011-12.http://www.fda.gov/.
[18] Draft guidance on estradiol. 2014-9. http://www.fda.gov/.
[19] Draft guidance on metronidazole.2013-4. http://www.fda.gov/.
[20] Draft guidance on miconazole nitrate. 2009-11. http://www.fda.gov/.
[21] Draft guidance on progesterone. 2012-9. http://www.fda.gov/.
[22] Draft guidance on terconazole. 2010-10. http://www.fda.gov/.
[23] Draft guidance on tioconazole. 2011-3. http://www.fda.gov/.
[24] Guideline on the investigation of bioequivalence. 2010: http://www.emau.europa.eu.
[25] Guideline on equivalence studies for the demonstration of therapeutic equivalence for products that are locally applied, locally acting in the gastrointestinal tract as addendum to the guideline on the clinical requirements for locally applied, locally acting products containing known constituents. 2017. http://www.emau.europa.eu.
[26] EU Clinical Trials Register. 2017 . http://www.Clinical Trials Register.eu/.
[27] Terconazole vaginal cream, 0.8% . 2004 . http://www.fda.gov/.
[28] Clidesse (clindamycin phosphate) vaginalcream, 2%. 2004 . http://www.fda.gov/.
[29] Clindamycin phosphate vaginal suppositories,100mg. 1999 . http://www.fda.gov/.
[30] Metronidazole vaginal gel,1.3%. 2014 . http://www.fda.gov/.
[31] Estradiol vaginal tablet. 1999. http://www.fda.gov/.
PDF(1039 KB)

266

Accesses

0

Citation

Detail
段落导航
相关文章

/

〈 〉